Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults

Journal of Clinical Lipidology

Volumn 8, Issue 1, 2014, Pages 86-93

  Kilgore, Meredith ^a   Muntner, Paul ^a,b   Woolley, J Michael ^c   Sharma, Pradeep ^a   Bittner, Vera ^b   Rosenson, Robert S ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c AMGEN INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol screening; Coronary heart disease; Dyslipidemia; Epidemiology; Practice guidelines

Indexed keywords

CHOLESTEROL SCREENING; CORONARY HEART DISEASE; DYSLIPIDEMIA; EPIDEMIOLOGY; PRACTICE GUIDELINES;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; NUTRITION SURVEYS; PREVALENCE; TRIGLYCERIDES; UNITED STATES;

EID: 84893972565     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.11.001     Document Type: Article

References (26)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. I. Graham, D. Atar, and K. Borch-Johnsen et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 suppl 2 2007 S1 S113
3. L. Ryden, E. Standl, and M. Bartnik et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
4. I. Graham, D. Atar, and K. Borch-Johnsen et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 suppl 2 2007 E1 E40
5. Y. Cui, R.S. Blumenthal, and J.A. Flaws et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1419
6. S. Lehto, T. Ronnemaa, S.M. Haffner, K. Pyorala, V. Kallio, and M. Laakso Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM Diabetes 46 1997 1354 1359
7. T. Pischon, C.J. Girman, F.M. Sacks, N. Rifai, M.J. Stampfer, and E.B. Rimm Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 112 2005 3375 3383
8. S.M. Boekholdt, B.J. Arsenault, and S. Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
9. A.D. Sniderman, D. Blank, R. Zakarian, J. Bergeron, and J. Frohlich Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula Clin Biochem 36 2003 499 504
10. S.H. Hsia Non-HDL cholesterol: into the spotlight Diabetes Care 26 2003 240 242
11. National Center for Health Statistics. NHANES Survey Questionnaires, Examination Components and Laboratory Components 2005-2006. Available at: http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/questexam05-06.htm. Accessed May 7, 2013.
12. K.G. Alberti, R.H. Eckel, S.M. Grundy International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
13. A.J. Barros, and V.N. Hirakata Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio BMC Med Res Methodol 3 2003 21
14. L. Baruch, V.J. Chiong, S. Agarwal, and B. Gupta Discordance of non-HDL and directly measured LDL cholesterol: which lipid measure is preferred when calculated LDL is inaccurate? Cholesterol 2013 2013 502948
15. E.M. Degoma, M.D. Davis, R.L. Dunbar, E.R. Mohler III, P. Greenland, and B. French Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis Atherosclerosis 229 2013 517 523
16. M.B. Elshazly, S.S. Martin, and M.J. Blaha et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in a clinical sample of 1.3 million adults: the VLDL-2 study (very large database of lipids) J Am Coll Cardiol 62 2013 1960 1965
17. A.D. Sniderman, K. Williams, and J.H. Contois et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
18. W. Lu, H.E. Resnick, and K.A. Jablonski et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study Diabetes Care 26 2003 16 23
19. V. Bittner, R. Hardison, and S.F. Kelsey et al. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 106 2002 2537 2542
20. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010 JAMA 307 2012 483 490
21. E.S. Ford, C. Li, and N. Sattar Metabolic syndrome and incident diabetes: current state of the evidence Diabetes Care 31 2008 1898 1904
22. L. Mosca, E.J. Benjamin, K. Berra American Heart Association Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association J Am Coll Cardiol 57 2011 1404 1423
23. C.M. Ballantyne, M. Bertolami, and H.R. Hernandez Garcia et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II Am Heart J 151 2006 975.e1 975.e9
24. A.F. Stalenhoef, C.M. Ballantyne, and C. Sarti et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study Eur Heart J 26 2005 2664 2672
25. R.G. Bakker-Arkema, M.H. Davidson, and R.J. Goldstein et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia JAMA 275 1996 128 133
26. D.B. Hunninghake, E.A. Stein, and H.E. Bays et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia Coron Artery Dis 15 2004 115 123